Insmed Incorporated (NASDAQ:INSM) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Insmed Incorporated (NASDAQ:INSM) by 33.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,615 shares of the biopharmaceutical company’s stock after selling 13,204 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Insmed were worth $1,838,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC raised its position in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the period. Spire Wealth Management acquired a new stake in shares of Insmed during the 4th quarter worth approximately $47,000. Smartleaf Asset Management LLC raised its position in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 411 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Insmed during the 4th quarter worth approximately $86,000.

Insider Activity at Insmed

In related news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $27,079,091.58. This trade represents a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at $9,545,887.53. This trade represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 88,232 shares of company stock worth $6,868,473. 3.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on INSM shares. Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. UBS Group dropped their target price on Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Wells Fargo & Company increased their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Finally, Stifel Nicolaus dropped their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

Insmed Stock Down 3.0%

Shares of INSM stock opened at $65.71 on Wednesday. The stock has a fifty day moving average price of $72.17 and a 200 day moving average price of $73.26. The stock has a market cap of $11.95 billion, a P/E ratio of -11.75 and a beta of 0.84. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same quarter last year, the firm posted ($1.06) EPS. The business’s revenue was up 22.9% on a year-over-year basis. Analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.